Johan Vijgen

Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation

Riccardo Cappato, Francis E. Marchlinski, Stefan H. Hohnloser et al. · European Heart Journal · 2015 · 426 citations · Full text

Multi-national survey on the methods, efficacy, and safety on the post-approval clinical use of pulsed field ablation (MANIFEST-PF)

Emmanuel Ekanem, Vivek Y. Reddy, Boris Schmidt et al. · EP Europace · 2022 · 310 citations · Full text

Safety and Effectiveness of Pulsed Field Ablation to Treat Atrial Fibrillation: One-Year Outcomes From the MANIFEST-PF Registry

Mohit K. Turagam, Petr Neužil, Boris Schmidt et al. · Circulation · 2023 · 303 citations · Full text

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

Jonathan P. Piccini, Valeria Caso, Stuart J. Connolly et al. · The Lancet · 2022 · 296 citations · Full text

Thrombosis, Dose-finding Phase 2, Cardiovascular Disease +10

Pulmonary Vein Isolation With Very High Power, Short Duration, Temperature-Controlled Lesions

Vivek Y. Reddy, Massimo Grimaldi, Tom De Potter et al. · JACC. Clinical electrophysiology · 2019 · 284 citations · Full text